A New Study on Lithium and Alzheimer’s Disease

A recent study from Harvard Medical School has drawn connections between reduced levels of lithium and Alzheimer’s disease, sparking some optimism among advocates on Long Island. They expressed that this area certainly needs more advancements.

The seven-year research could potentially aid in detecting Alzheimer’s at earlier stages, propose new treatment options, and enhance our overall understanding of brain functions, according to the study’s authors.

“This is probably the most promising news we’ve had recently,” shared Tori Cohen, executive director of the Long Island Alzheimer’s and Dementia Center in Westbury. She emphasized the importance of pursuing this information vigorously.

Lauren Vlachos, leading the Alzheimer’s Disease Resource Center in East Islip, described the findings as “an exciting moment in Alzheimer’s research.” She pointed out the recent Harvard study that indicated lithium orotate might reverse Alzheimer’s-like changes in mice, calling it a significant breakthrough that renews hope for both treatment and prevention.

Vlachos also highlighted the necessity for ongoing funding in research while advocating for these findings to transition into clinical trials. “Discovery is just part of the journey,” she noted.

However, one Long Island expert tempered the enthusiasm, warning that the study’s findings are preliminary. Dr. Marc Gordon, chief of neurology at Northwell’s Zucker Hillside, cautioned against individuals rushing to take lithium pills. “I worry that people might misunderstand the results and start using lithium carbonate irresponsibly,” he commented.

The exploration, led by Dr. Bruce A. Yankner, a professor at Harvard, demonstrated that researchers successfully reversed Alzheimer’s symptoms in mice using small doses of lithium orotate, mimicking natural levels of lithium found in the brain.

The research results were published in the journal Nature on Wednesday. “The key takeaway is that since lithium orotate is very inexpensive, it ideally should lead to rigorous trials fairly quickly,” suggested Matt Kaeberlein, who previously directed the Healthy Aging and Longevity Research Institute at the University of Washington. He emphasized the urgency, stating that it would be embarrassing for the Alzheimer’s clinical community if swift actions aren’t taken.

Yankner echoed the need for caution, making it clear not to recommend lithium consumption at this stage, given that the treatment’s efficacy in humans hasn’t been confirmed. He pointed out the necessity for additional laboratories to verify these findings.

Despite being conducted with mice, Cohen mentioned that the study’s implications should not be dismissed regarding potential applications in humans.

Alzheimer’s is a form of dementia impacting memory, thought processes, and behavior. Current estimates indicate that over 7 million Americans aged 65 and older are living with Alzheimer’s, with projections suggesting this number could approach 13 million by 2050.

While recent discoveries in Alzheimer’s treatment are promising, no definitive medication exists to stop or reverse the disease. Lithium is routinely prescribed for individuals with bipolar disorder, and past studies have hinted that it may also assist in Alzheimer’s treatment or serve anti-aging purposes. A 2017 study from Denmark even indicated that lithium found in drinking water could link to lower dementia rates.